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Abstract
Background: Cost-Effectiveness Analysis (CEA) has been promoted as an important research methodology for determining
the efficiency of healthcare technology and guiding medical decision-making. Our aim was to characterize the collaborative
patterns of CEA conducted over the past two decades in Spain.
Methods and Findings: A systematic analysis was carried out with the information obtained through an updated
comprehensive literature review and from reports of health technology assessment agencies. We identified CEAs with
outcomes expressed as a time-based summary measure of population health (e.g. quality-adjusted life-years or disability-
adjusted life-years), conducted in Spain and published between 1989 and 2011. Networks of coauthorship and institutional
collaboration were produced using PAJEK software. One-hundred and thirty-one papers were analyzed, in which 526
authors and 230 institutions participated. The overall signatures per paper index was 5.4. Six major groups (one with 14
members, three with 7 members and two with 6 members) were identified. The most prolific authors were generally
affiliated with the private-for-profit sector (e.g. consulting firms and the pharmaceutical industry). The private-for-profit
sector mantains profuse collaborative networks including public hospitals and academia. Collaboration within the public
sector (e.g. healthcare administration and primary care) was weak and fragmented.
Conclusions: This empirical analysis reflects critical practices among collaborative networks that contributed substantially to
the production of CEA, raises challenges for redesigning future policies and provides a framework for similar analyses in
other regions.
Citation: Catala ´-Lo ´pez F, Alonso-Arroyo A, Aleixandre-Benavent R, Ridao M, Bolan ˜os M, et al. (2012) Coauthorship and Institutional Collaborations on Cost-
Effectiveness Analyses: A Systematic Network Analysis. PLoS ONE 7(5): e38012. doi:10.1371/journal.pone.0038012
Editor: Attila Szolnoki, Hungarian Academy of Sciences, Hungary
Received March 13, 2012; Accepted April 29, 2012; Published May 29, 2012
Copyright:  2012 Catala ´-Lo ´pez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ferran_catala@hotmail.com
Introduction
In recent years, rising demand and constrained resources–
enhanced by the recent economic and financial crisis–is making
cost-effectiveness one of the most important goals in healthcare.
Cost-effectiveness analysis (CEA), sometimes part of the health
technology assessment process, involves the comparisons of
alternative options in terms of their costs and their outcomes.
CEA has been promoted as an important research methodology
for determining the efficiency of healthcare technology and
guiding societal decision-making on the financing of public
healthcare services. At the same time, and as was the case with
clinical research [1–4], conflicts of interest due to the influence of
the pharmaceutical and medical technology industries is emerging
as a critical issue in economic research [5,6].
Although there is some controversy about the role of CEA in
decision-making at the level of healthcare administrations and
individual hospitals, various national healthcare systems are now
using economic evidence to make system-level decisions about
which interventions to fund from collective resources [7], with
Australia, New Zealand, the United Kingdom and Canada
pioneering this scheme [8,9]. In other countries, the regulatory
and institutional framework has so far not helped the introduction
of CEAs and their application to the decisions of public health
funding. Such is the case in Spain, where the 2006 Pharmaceu-
ticals and Healthcare Products Law [10] avoided any explicit
reference to cost-effectiveness. Recently, the 2011 package of
measures to reduce fiscal deficit incorporated the possibility of
using economic criteria in the price-fixing decisions, but
uncertainties about the specific role CEA will play in the market
access of new medicines and healthcare products still remain
[11,12], including the scientific capacity of the research structures
to produce the cost-effectiveness studies that the Spanish
healthcare system needs.
A comprehensive systematic analysis of current scientific activity
and practice is critical to understanding the maturity and growth
of any research area [13]. Social network analysis is grounded in
the assessment of empirical data and can provide an appropriate
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e38012approach to identify researchers, groups and organizations. It also
offers highly interesting information to understand the structure
and nature of relationships and interaction within a scientific
community [14–17]. This study aims to describe and characterize
collaborative patterns on CEA conducted over the past two
decades in Spain, applying techniques from social network analysis
and bibliometrics.
Methods
Comprehensive Systematic Review of CEAs
We updated a previous comprehensive literature review which
had examined CEAs conducted in Spain within the period 1983–
2008 [18,19], adding the studies published until September 2011.
Briefly, this systematic review was conducted in PubMed/MED-
LINE, SCOPUS, ISI Web of Knowledge, Databases of the Centre
for Reviews and Dissemination (CRD), as well as I ´ndice Me ´dico
Espan ˜ol (IME) and I ´ndice Bibliogra ´fico Espan ˜ol en Ciencias de la Salud
(IBECS). Medical subject heading (MeSH) descriptors were used
distributed into two blocks: economic evaluation and Spain. In
addition, hand searches were carried out for reports from health
technology assessment agencies and papers in specialized local
journals partially included in the abovementioned databases.
Reviews, editorials and abstracts of congresses were excluded.
Our selection of articles was based on the criteria of full
economic evaluation (evaluations where both costs and health
outcomes have been measured) of healthcare interventions. In
particular, this study focuses on CEAs that use outcomes as a time-
based summary measure of population health that captures both
prolongation and health-related quality of life (e.g. quality-adjusted
life-years [QALYs] or disability-adjusted life years [DALYs]), also
known as ‘‘cost-utility analyses’’. We selected this type of CEA
because many decision-makers and researchers have recom-
mended the QALY/DALY framework as the standard reference
for cost-effectiveness [20,21].
For each paper selected, we recorded the year of publication,
the journal title, country of publishing editor (local or internation-
al), the name and surnames of the authors as well as their
institutional affiliation. Journals were classified as medical and
clinical journals (e.g. Current Medical Research and Opinion,
Revista de Neurologı ´a, Clinical and Translational Oncology) or
economics, health policy, and health services research journals
(e.g. PharmacoEconomics, Gaceta Sanitaria, European Journal of
Health Economics, reports of Health Technology Assessment).
The journals’ impact factor was obtained from the 2010 Journal
Citation Reports (JCR) and was categorized into quartiles. We
used the expanded Science Citation Index (ISI Web of Knowl-
edge) to determine the extent to which each study has been cited in
other publications. To homogenize authorship, we checked the
signatures with which an individual appeared in two or more
different forms, using coincidence in authors’ places of work as the
basic criterion for normalization. In the case of institutions, we
have unified the different variants to match the name recorded in
the Spanish National Catalogue of Hospitals, the National
Registry of Universities and public directories of institutions.
Similarly, given that institutional names in many records included
two or more institutions (e.g. university hospitals and academia;
consulting firms and academia), we have proceeded to distinguish
between these signatures by recording as many signatures as
individual macroinstitutions could be identified for each biblio-
graphic record. With this information we constructed a Microsoft
Access database.
Indicators and Networks of Coauthorship and of
Institutional Collaboration
We use the term coauthorship to refer to joint authorship of
a scientific paper by 2 individuals, and institutional collaboration to
refer to joint authorship by different institutions. Intensity of
collaboration or threshold refers to the figure used to form clusters
of authors and institutions, referring to the frequency of coauthor-
ship between pairs of authors or of collaboration between
institutions, and reflects a criterion to label identifiable clusters
as research groups.
Collaboration between authors is portrayed by calculating the
number of papers, signatures, collaborations, the index of
signatures per paper or collaboration index, which is the mean
number of signatures per paper; and the index of authors per
paper (mean number of authors per paper considering only the
different authors).
Table 1. Characteristics of cost-effectiveness analyses, 1989–
2011 (n=131).
Characteristics Number % of total
Year of publication
1989–1995 3 2.3
1996–2000 8 6.1
2001–2005 19 14.5
2006–2011 101 77.1
Journals containing 3 or more papers
PharmacoEconomics - Spanish Research Articles 10 7.6
Health Technology Assessment reports 9 6.8
Revista Espan ˜ola de Economı ´a de la Salud 8 6.1
Gaceta Sanitaria 7 5.3
European Journal of Health Economics 4 3.0
Current Medical Research and Opinion 4 3.0
Clinical and Translational Oncology 4 3.0
Revista de Neurologı ´a 4 3.0
Value in Health 4 3.0
Osteoporosis International 3 2.3
PharmacoEconomics 3 2.3
Revista Espan ˜ola de Salud Pu ´blica 3 2.3
Vaccine 3 2.3
Vacunas 3 2.3
Journal type
Medical and clinical 77 58.8
Economics, health policy and health
Services research
54 41.2
Origin of publication
Local/sub-national level 67 51.1
International 64 48.9
JCR 2010 impact factor, quartiles (Q)
Q1 29 22.1
Q2 23 17.6
Q3 18 13.7
Q4 13 9.9
None 48 36.6
JCR: Journal Citation Report, year 2010.
doi:10.1371/journal.pone.0038012.t001
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tions of pairs of authors for each paper. The number of
coauthorships for each paper is related to the number of authors
as it is equal to m!/(m-n)!n!, where m is the number of individual
authors and n the number of elements in the groups constructed.
Once coauthorship was quantified, we further established
a threshold of 2 or more collaborations between pairs of authors
to reduce the number of nodes and links that would prevent a clear
view of the network and thus centre analysis on the more intense
coauthorship relationships. The same approach was applied to
institutional authorship to construct the network of interinstitu-
tional collaboration, although in this case we applied a threshold of
Figure 1. Full network of coauthorship. Note: Each circle represents one author and each line connecting two of them reflects the presence of at
least one paper they have co-authored.
doi:10.1371/journal.pone.0038012.g001
Figure 2. Full network of institutional collaboration. Note: Each circle represents one institution and each line connecting two of them reflects
the presence of at least one paper they have co-authored.
doi:10.1371/journal.pone.0038012.g002
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indicators and construct social networks.
Results
Data on 131 articles published between 1989 and 2011 was
judged to contain eligible CEAs and became part of the analysis.
Ninety-nine percent of the papers were signed in collaboration by
two or more authors; 710 signatures were identified for an overall
collaboration index of 5.4 signatures per paper.
The number of publications increased exponentially over the
study period (Table 1). More than three-quarters of the CEAs
were carried out during 2006–2011. PharmacoEconomics –
Spanish Research Articles was the journal that published the
greatest number of manuscripts (n=10; 7.6%), followed by reports
for the Health Technology Assessment agencies (n=9; 6.8%),
Revista Espan ˜ola de Economı ´a de la Salud (n=8; 6.1%) and Gaceta
Sanitaria (n=7; 5.3%). Nearly 40% (n=52) of the CEAs were
published in journals within the first and second quartile of their
speciality. By journal type, 59% (n=77) of the studies were
Table 2. Ranking of most productive authors and their collaborative patterns.
Ranking Author Affiliation (type) Papers Signatures
a Authors/paper index Collaborators
a
1 Brosa-Riestra M Oblikue Consulting (consulting firm) 15 98 6.5 73
2 Rubio-Terre ´s C HERO Consulting (consulting firm) 11 56 5.1 40
3 Rodrı ´guez-Barrios JMMedtronic Ibe ´rica S.A. (pharmaceutical
industry)
8 59 7.4 46
4 Casado MA PORIB (consulting firm) 7 36 5.1 20
5 Mar J Hospital Alto Deba (hospital) 7 25 3.6 17
6L o ´pez-Bastida J Servicio Canario de Salud (healthcare administration) 6 28 4.7 21
7 Crespo C Oblikue Consulting, Universidad Auto ´noma
de Barcelona (consulting firm, academia)
5 48 9.6 38
8 Oyagu ¨ez I PORIB (consulting firm) 5 30 6.0 21
9D ı ´az-Cerezo S Pfizer S.A. (pharmaceutical industry) 5 30 6.0 19
10 Rejas-Gutie ´rrez J Pfizer S.A. (pharmaceutical industry) 5 27 5.4 17
11 Buti M Hospital Vall d’Hebro ´n (hospital) 5 25 5.0 14
12 Dilla T Lilly S.A. (pharmaceutical industry) 4 22 5.0 15
13 Haro JM Fundacio ´ Sant Joan de Deu (hospital) 4 24 6.0 14
14 Jo ¨nsson B Stockholm School of Economics (academia) 4 37 9.2 33
15 Badı ´a X IMS Health S.A. (consulting firm) 3 18 6.0 15
aIn papers where the author has participated. Authors in bold indicate authors affiliated with private-for-profit sector.
doi:10.1371/journal.pone.0038012.t002
Figure 3. Clusters of authors applying a threshold of two or more papers signed in coauthorship.
doi:10.1371/journal.pone.0038012.g003
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show the structure of the full networks, in which 526 authors and
230 institutions participated. The network’s size (given by the
number of nodes) is discernable and not visually dense (given by
the number of connections).
We identified 14 authors who published more than 3 papers.
The most prolific authors (Table 2) were Brosa-Riestra and Rubio-
Terre ´s with 15 and 11 papers, respectively. Two thirds of the 14
most prolific authors were affiliated with consulting firms and/or
the pharmaceutical and medical technology industries. Applying
a threshold of two or more papers signed in coauthorship
(Figure 3), we identified 15 clusters of authors. Of them, 6 major
groups (one with 14 members, three with 7 members and two with
6 members) were identified; 4 of these 6 most collaborative
authors’ clusters included at least one industry-affiliated author-
ship.
Institutional productivity was headed by Oblikue Consulting
and Pfizer S.A. with 14 papers each (Table 3). Next came the
Universidad Auto ´noma de Barcelona and HERO Consulting with 12
and 10, respectively, and Medtronic Ibe ´rica S.A., Hospital Vall d’Hebro ´
Table 3. Ranking of most productive institutions and their collaborative patterns.
Ranking Institution (type) Papers Signatures Collaborations Collaborators
1 Oblikue Consulting (consulting firm) 14 81 14 50
2 Pfizer S.A. (pharmaceutical industry) 14 62 14 32
3 Universidad Auto ´noma de Barcelona (academia) 12 68 11 43
4 HERO Consulting (consulting firm) 10 34 10 18
5 Medtronic Ibe ´rica S.A. (pharmaceutical industry) 8 47 8 30
6 Hospital Vall d’Hebron (hospital) 8 39 7 29
7 Hospital Clı ´nic de Barcelona (hospital) 8 29 7 15
8 Hospital Universitario 12 de Octubre (hospital) 7 28 6 20
9 Complejo Universitario San Carlos (hospital) 6 35 6 27
10 Complejo Universitario La Paz (hospital) 6 34 6 23
11 Hospital Alto Deba (hospital) 6 21 6 13
12 Pfizer Inc. USA (pharmaceutical industry) 5 25 5 14
13 Fundacio ´ Sant Joan de De ´u (hospital) 4 18 4 9
14 Merck and Co., Inc. (pharmaceutical industry) 3 16 3 13
15 Hospital Universitari de Bellvitge (hospital) 2 22 15 2
Institutions in bold indicate private-for-profit sector.
doi:10.1371/journal.pone.0038012.t003
Figure 4. Clusters of institutions applying a threshold of three or more papers signed in institutional collaboration.
doi:10.1371/journal.pone.0038012.g004
Collaboration Networks on Cost-Effectiveness
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e38012and Hospital Clı ´nic de Barcelona with 8 each. Applying a collaboration
threshold of at least 3 papers signed with interinstitutional
collaboration, we identified 11 clusters comprising by a total of
56 institutions (Figure 4 and 5). The private-for-profit sector
mantains broad collaborative networks including public hospitals
and academia. Collaboration within the public sector (e.g.,
healthcare administration and primary care) was weak and
fragmented.
Among the 34 authors who published the top-10 most cited
CEAs (Table 4), only 5 (13%) are among the top-15 most prolific
authors. The article by Mar and Rodrı ´guez-Artalejo [23] was the
most frequently cited. Only one author appeared more than once
in the top-10 most cited CEAs list, with 3 papers [23–25]
attracting 120 citations. Since older articles are more likely to
generate more citations, only three out of the top-10 were
published in the second half of the 2000s.
Discussion
Our paper synthesizes empirical data on the development of
CEAs in Spain using social network analysis. This methodology
allowed us to identify the most productive authors and institutions,
as well as the structure and patterns of collaboration that have
published papers over a 22-year period. Perhaps the most
significant finding is that networks of scientific collaboration
reveal a discernable and limited scientific community, with most
individuals having only a few coauthors, whereas a few firms have
many collaborations. Remarkably, the scientific community
captured by the network analysis is centred on a nucleus of
authors from private-for-profit companies (consulting firms and
the pharmaceutical industry) and affiliated collaborators from
hospitals and academia.
Very few studies have reviewed CEAs using social network
analysis, and although not directly comparable with our analysis,
there are aspects worthy of comment. The recent study by
Greenberg et al.[26], a CEA review of the English-language
articles indexed in PubMed/MEDLINE since 2006, observed that
the most prolific authors were affiliated with renowned academic
and hospital centres but did not find any substantial private-for-
profit (e.g. pharmaceutical industry) relationships across groups.
These differences with our results are striking and probably part of
the different public and academic commitment to health services
research and CEA studies in Spain. However, the inclusion of all
types of studies –regardless of language or publication status and
indexing in bibliographic databases– may be a contributing factor
to these differences: more than one-third of our selected articles
were published in non-indexed journals with clear links to
commercial third parties, while Greenberg et al [26] used only
PubMed/MEDLINE indexed papers.
There are several possible explanations for our findings.
Industry funds an increasing proportion of medical research
[27]. Cost-effectiveness is aimed at reducing resource allocation
and may have significant implications on public decisions,
therefore industry-funded CEAs may be part of promotional
strategies aimed at demonstrating that new products are cost-
Figure 5. Institutional collaboration network.
doi:10.1371/journal.pone.0038012.g005
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activities. Other important health policy questions with no
commercial connections would not be supported by the private
sector, and therefore the Spanish CEA literature is probably
reflecting the research priorities of private industry rather than
informing policy-makers on efficient ways to afford the health
needs of the population [18]. Additionally, a growing body of
literature has been drawing attention to the fact that industry-
sponsored studies are more likely than non-industry sponsored
studies to report results and conclusions favouring the sponsor’s
product or to report more favourable cost-effectiveness ratios
[5,6,28–34]. In fact, negative industry-sponsored CEA studies are
extremely infrequent. Overall, we are facing a literature with
a high risk of bias. The high prevalence of studies conducted or
funded by commercial third parties could lead to a reduction in
the credibility and actual use of this type of research [35]. In fact,
few decision-makers anywhere in the industrialized countries seem
to rely on these types of analyses in their decisions [36]. Exceptions
include countries with well-established public agencies, such as
NICE in the United Kingdom [37].
In Spain, the central government is the main decision-maker in
pricing and reimbursement related to new medicines, but
traditionally there have been no national requirements related to
the cost-effectiveness of new medicines. A direct consequence of
this situation is that the public sector may have indeed lost control
of the CEA research agenda. Despite recent policies of promoting
interinstitutional collaboration and public network research [38],
we have only detected small clusters in which the institutions
involved are public ones, denoting a clear underrepresentation of
the healthcare administration. Similarly, few authors from the
public sector seem to produce these types of analyses, and those
who do so are scientifically isolated (although they published the
most influential studies). This context is changing with the
introduction of new policy measures and the creation of new
policy-oriented committees, but cutbacks in funding health
research in Spain will not facilitate the development of an
independent publicly funded CEA research network.
Our study has several limitations. First, although the scientific
production analyzed has been drawn from an exhaustive,
comprehensive review of original research of cost-effectiveness
studies, it is possible that the search missed some articles with
relevant elements or that some studies conducted by manufac-
turers may not have been published. The analyses inevitably
represent only a first overview of research in this area.
Furthermore, we restricted our analysis to CEAs that measured
health outcomes with QALYs or DALYs, and therefore there may
be researchers (and institutions) who do not appear because their
publications are not reflected in the networks. It would be
interesting to explore whether the use of alternative outcome
measurements results in similar patterns of collaborations. Our
analysis was also limited in scope, focusing as it does only on
original cost-effectiveness research. Undoubtedly, there are other
important reports (including reviews of economic evaluations) that
also merit consideration in decision-making. Second, the networks
identified primarily reflect recent publications (more than three-
quarters of the papers were published in the last 5 years). Given
the dynamic nature of research, other opportunities for further
research include examining the evolution of the identified
networks over time (e.g. by means of longitudinal social network
analysis). Third, as in many other bibliometric analyses, the
importance of normalizing the names of authors and institutions is
fundamental to avoiding errors caused in recognizing variations in
the name of a single author, or considering scientific production of
2 or more different authors with the same names as belonging to
Table 4. List of most cited cost-effectiveness analyses (with at least one Spanish author).
Ranking Authors Title Journal Year Citations
1 Mar J, Rodrı ´guez-Artalejo F. Which is more important for the efficiency of hypertension
treatment: hypertension stage, type
of drug or therapeutic compliance?
Journal of
Hypertension
2001 53
2 Buti M, Casado MA, Fosbrook L,
Wong JB, Esteban R.
Cost-effectiveness of combination therapy for naive patients
with chronic hepatitis C
Journal of
Hepatology
2000 47
3A n ˜o ´n JM, Garcı ´a de Lorenzo A,
Zarazaga A, Go ´mez Tello V,
Garrido G.
Mechanical ventilation of patients on long-term oxygen
therapy with acute exacerbations of chronic obstructive
pulmonary disease: prognosis and cost-utility analysis
Intensive Care Medicine 1999 39
4 Mar J, Rueda JR, Dura ´n Cantolla J,
Schechter C, Chilcott J.
The cost-effectiveness of nCPAP treatment in patients
with moderate-to-severe obstructive sleep apnoea
European Respiratory
Journal
2003 36
5 Mar J, Begirista ´in JM, Arrazola A. Cost-effectiveness analysis of thrombolytic treatment
for stroke
Cerebrovascular Diseases 2005 31
6 Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma
Instead of standard plasma
Transfusion 1999 29
7 Latour-Pe ´rez J, Navarro-Ruiz A,
Ridao-Lo ´pez M, Cervera-Montes M.
Using clopidogrel in non-ST-segment elevation acute
coronary syndrome patients: a cost-utility analysis
in Spain
Value in Health 2004 24
8 Plans-Rubio ´ P, Garrido-Morales
P, Salleras Sanmartı ´ L.
The cost-effectiveness of pneumococcal vaccination
in Catalonia
Revista Espan ˜ola de
Salud Pu ´blica
1995 24
9 Rodrı ´guez MJ, Dı ´az-Cerezo S,
Vera Llonch M, Dukes E,
Rejas-Gutie ´rrez J.
Cost-effectiveness analysis of pregabalin versus gabapentin
in the management of neuropathic pain due to diabetic
polyneuropathy or post-herpetic neuralgia
Current Medical
Research and Opinion
2007 19
10 Rutten Van Mo ¨lken MP,
Oostenbrink JB, Miravitlles M,
Monz BU.
Modelling the 5-year cost effectiveness of tiotropium,
salmeterol and ipratropium for the treatment of chronic
obstructive pulmonary disease in Spain
European Journal of
Health Economics
2007 19
Authors in bold indicate prolific authors according to number of publications (Table 1).
doi:10.1371/journal.pone.0038012.t004
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validation of the bibliographic references to avoid these errors.
Fourth, in a context of scientific literature dominated by market
orientation, we can expect some presence of ghostwriters and
honorary authorships [39–41], there being some indirect evidence
of these practices [42]. Ghostwriters and honorary authorships
could distort the real CEA networks, reducing the importance of
private firms and falsely increasing the academic presence. Finally,
the analysis of coauthorship and institutional collaborations for
constructing networks has only recently become an object of study
in health services research, and uniform criteria to identify
communities or research groups within previously constructed
networks are generally lacking. This may explain some of the
differences in the observed patterns of authorship and institutional
collaboration with other studies [26], especially because reports
identified outside widely-used databases and readily accessible
journals may be of lower quality than studies that are easier to
access [43].
In summary, our study reflects current critical practices among
collaborative networks that contribute substantially to the pro-
duction of CEAs in Spain, raises challenges for redesigning future
policies and provides a framework for similar analyses in other
regions. We believe there is an urgent need to implement cost-
effectiveness criteria together with clinical effectiveness and safety
to assess what it may be realistic to pay for health gains. In Spain,
the credibility of current fiscal adjustments and the solvency of the
National Health System will depend primarily on the ability to
evolve rapidly towards the selective funding of healthcare
technologies, including new price-fixing schemes to ensure value-
for-money for new medicines, and therefore evidence-based
policies. Rational structural changes are required in the current
procedures. Moreover, as the government and local healthcare
administrations increasingly have a role in decisions related to
cost-effectiveness, a well-connected and coordinated network
becomes more important. Incentivizing the sustained involvement
of researchers in the public health sector potentially addresses the
lack of technical capacities and needs, as well as facilitating
cooperation between researchers and policy-makers [44]. Com-
plementary options might include the establishment of a board or
independent agency that includes policy-makers as well as
researchers to develop and/or approve a common cost-effective-
ness research agenda that is relevant to health policy.
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